Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Metabolic medicine

Long-Term Management and Diet

At a Glance

Long-term CPS1 deficiency care combines an individualized protein allowance with enough calories, specialized formula, prescribed medicines, and regular growth and blood-test monitoring. A written sick-day plan helps prevent illness-related ammonia crises.

Managing CPS1 deficiency is a lifelong balancing act. The goal is to provide enough protein and energy for your child to grow and thrive while keeping ammonia levels safely low [1][2]. This requires a highly individualized plan coordinated by a metabolic specialist and a metabolic dietitian [3][4].

The Individualized Diet

Protein contains nitrogen, which the body turns into ammonia. Because the CPS1 enzyme is deficient, your child cannot process this nitrogen effectively.

  • Restricted, Not Eliminated: Protein is essential for growth. Instead of eliminating it entirely, your dietitian calculates a strict, individualized daily allowance of “natural protein” from regular foods [1]. You should never change this allowance without their guidance.
  • Specialized Formulas: To ensure your child gets enough energy and essential nutrients, they will use a specialized medical formula [1][2]. These formulas are tailored to provide specific essential amino acids or nitrogen-equivalents that are less likely to overwhelm the compromised urea cycle [5].
  • Calorie Focus: Providing enough calories from carbohydrates and fats is vital. If a child doesn’t eat enough calories, their body begins to break down its own muscle (catabolism), which releases a surge of ammonia [6][7].

Daily Medications

Medications act as a safety net, providing alternative ways for the body to get rid of nitrogen [8]. These must be taken exactly as prescribed; independent dose adjustments are dangerous.

  • Nitrogen Scavengers: Medications like oral sodium phenylbutyrate [9] or glycerol phenylbutyrate [10] scavenge nitrogen from the blood and allow it to be peed out. These require prescribed dosing and laboratory monitoring [11][12]. Sodium-containing scavengers can affect sodium and acid-base balance.
  • Amino Acid Supplements: Because the urea cycle is blocked early, the body runs out of later products. L-Citrulline [13] or L-Arginine supplements are prescribed based on the patient’s specific metabolic profile and blood levels [14][15].

If your child cannot keep their medication down due to vomiting, or misses a dose, follow your sick-day plan and contact the metabolic team immediately.

Monitoring Growth and Labs

Because your child’s needs change as they grow, regular “check-ups” with the metabolic team are essential.

  • Growth Tracking: Doctors will closely monitor height, weight, and head circumference. If growth slows down, it may be a sign that the diet is too restrictive or that the child isn’t getting enough total calories [16][17].
  • Blood Tests: You will regularly check ammonia and plasma amino acids.
    • Glutamine: High glutamine levels suggest that the body is struggling to manage its nitrogen load, even if the ammonia level looks normal [18][19].
    • Branched-Chain Amino Acids (BCAAs): Monitored to ensure the diet is not too restrictive and growth is supported [20].
  • Developmental Assessments: Regular screenings for learning, behavior, and motor skills help ensure that any subtle impacts of the condition are caught and supported early [16][21].

Always have a written Sick-Day Plan provided by your metabolic team. This plan tells you exactly how to adjust diet and medications during a fever or minor illness to prevent a full-blown crisis [6].

Common questions in this guide

Why is protein limited but not completely removed in CPS1 deficiency?
Protein contains nitrogen that the body converts into ammonia, which can build up when CPS1 does not work properly. Protein is still needed for growth, so a metabolic dietitian sets an individualized amount rather than removing it completely.
Why does my child need a special formula for CPS1 deficiency?
A specialized medical formula helps provide enough calories and essential nutrients while controlling the types and amount of nitrogen the body receives. The formula and natural protein allowance should be selected and adjusted by the metabolic dietitian.
What medicines are commonly used for long-term CPS1 deficiency care?
Sodium phenylbutyrate and glycerol phenylbutyrate help the body remove nitrogen through an alternate route. L-citrulline or L-arginine may also be prescribed to replace substances that become low when the urea cycle is blocked. Doses require medical supervision and laboratory monitoring.
What should I do if my child vomits or misses a CPS1 medicine dose?
Follow the written sick-day plan provided by the metabolic team and contact the team immediately. Do not independently change medication doses or wait for symptoms to become severe, because illness, vomiting, and missed doses can lead to a rapid ammonia rise.
How is my child's CPS1 deficiency monitored over time?
The metabolic team tracks height, weight, and head growth, along with ammonia and plasma amino acid levels. Nutritional tests and developmental screenings may also be used to identify dietary deficiencies or learning, behavior, and motor concerns early.
When should my child's protein allowance and medicine doses be reassessed?
They should be reviewed regularly as your child grows, becomes more active, or has changes in laboratory results, growth, or health. The metabolic team uses growth measurements, blood tests, dietary intake, and clinical needs to decide when adjustments are appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's current protein-to-energy ratio, and how does it compare to the recommendations for their age?
  2. 2.What specific plasma glutamine and ammonia levels are we aiming for to ensure their long-term metabolic stability?
  3. 3.Would my child benefit from switching to glycerol phenylbutyrate for better palatability or a reduced pill/volume burden?
  4. 4.How often will we perform nutritional labs to check for deficiencies in vitamins, trace elements, or essential amino acids?
  5. 5.At what point in my child's growth should we reassess their protein prescription and medication doses?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Treatment and management for children with urea cycle disorder in chronic stage.

    Huang X

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):744-750 doi:10.3724/zdxbyxb-2023-0378.

    PMID: 37807629
  2. 2

    Primary hyperammonaemia: Current diagnostic and therapeutic strategies.

    Häberle J

    Journal of mother and child 2020; (24(2)):32-38 doi:10.34763/jmotherandchild.20202402si.2015.000006.

    PMID: 33179600
  3. 3

    A case of late-onset carbamoyl phosphate synthetase 1 deficiency: diagnostic challenges and management in a low-resource setting.

    Cui X, Guo S, Zhang Y, et al.

    Clinical biochemistry 2026; (141()):111041 doi:10.1016/j.clinbiochem.2025.111041.

    PMID: 41242372
  4. 4

    N-carbamoylglutamate-responsive carbamoyl phosphate synthetase 1 (CPS1) deficiency: A patient with a novel CPS1 mutation and an experimental study on the mutation's effects.

    Yap S, Gougeard N, Hart AR, et al.

    JIMD reports 2019; (48(1)):36-44 doi:10.1002/jmd2.12034.

    PMID: 31392111
  5. 5

    Impact of long-term nitrogen scavenger therapy on clinical outcome in individuals with urea cycle disorders.

    Posset R, Epp F, Garbade SF, et al.

    Scientific reports 2026; (16(1)).

    PMID: 41851188
  6. 6

    The Therapeutic Hypothermia in Treatment of Hyperammonemic Encephalopathy due to Urea Cycle Disorders and Organic Acidemias.

    Ninković D, Mustapić Ž, Bartoniček D, et al.

    Klinische Padiatrie 2019; (231(2)):74-79 doi:10.1055/a-0855-4001.

    PMID: 30870873
  7. 7

    Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy.

    Das AM

    Metabolic brain disease 2025; (40(5)):192 doi:10.1007/s11011-025-01619-5.

    PMID: 40285952
  8. 8

    Nitrogen Scavengers: History, Clinical Considerations and Future Prospects.

    Klassa S, Häberle J

    Journal of inherited metabolic disease 2025; (48(6)):e70110 doi:10.1002/jimd.70110.

    PMID: 41163474
  9. 9

    Direct replacement of oral sodium benzoate with glycerol phenylbutyrate in children with urea cycle disorders.

    Yeo M, Rehsi P, Dorman M, et al.

    JIMD reports 2022; (63(2)):137-145 doi:10.1002/jmd2.12274.

    PMID: 35281661
  10. 10

    Impact of glycerol phenylbutyrate on biochemistry and outcomes in paediatric patients with urea cycle disorders: a multicentre case series from Saudi Arabia.

    Hejazi R, Alghamdi TH, Salih R, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 41618427
  11. 11

    Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study.

    Husson MC, Schiff M, Fouilhoux A, et al.

    Orphanet journal of rare diseases 2016; (11(1)):127 doi:10.1186/s13023-016-0513-0.

    PMID: 27663197
  12. 12

    Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre.

    Yeo M, Rehsi P, Dorman M, et al.

    JIMD reports 2023; (64(5)):317-326 doi:10.1002/jmd2.12386.

    PMID: 37701329
  13. 13

    Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea-cycle disorders: On the basis of information from a European multicenter registry.

    Molema F, Gleich F, Burgard P, et al.

    Journal of inherited metabolic disease 2019; (42(6)):1162-1175 doi:10.1002/jimd.12066.

    PMID: 30734935
  14. 14

    Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder.

    Diez-Fernandez C, Häberle J

    Expert opinion on therapeutic targets 2017; (21(4)):391-399 doi:10.1080/14728222.2017.1294685.

    PMID: 28281899
  15. 15

    Citrulline in the management of patients with urea cycle disorders.

    Imbard A, Bouchereau J, Arnoux JB, et al.

    Orphanet journal of rare diseases 2023; (18(1)):207 doi:10.1186/s13023-023-02800-8.

    PMID: 37480106
  16. 16

    Long-term follow-up of children with carbamoyl phosphate synthase 1 deficiency detected in newborn screening.

    Zhang Z, Tong F, Chen C, et al.

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):721-726 doi:10.3724/zdxbyxb-2023-0359.

    PMID: 37986659
  17. 17

    Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment.

    Molema F, Gleich F, Burgard P, et al.

    Molecular genetics and metabolism 2019; (126(4)):397-405 doi:10.1016/j.ymgme.2019.02.003.

    PMID: 30827756
  18. 18

    Novel Pathogenic Variant (c.580C>T) in the CPS1 Gene in a Newborn With Carbamoyl Phosphate Synthetase 1 Deficiency Identified by Whole Exome Sequencing.

    Choi R, Park HD, Yang M, et al.

    Annals of laboratory medicine 2017; (37(1)):58-62 doi:10.3343/alm.2017.37.1.58.

    PMID: 27834067
  19. 19

    Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned.

    Lin HT, Enchautegui-Colon Y, Huang YR, et al.

    Molecular genetics and metabolism reports 2022; (33()):100942 doi:10.1016/j.ymgmr.2022.100942.

    PMID: 36466970
  20. 20

    Long-term effects of medical management on growth and weight in individuals with urea cycle disorders.

    Posset R, Garbade SF, Gleich F, et al.

    Scientific reports 2020; (10(1)):11948 doi:10.1038/s41598-020-67496-3.

    PMID: 32686765
  21. 21

    Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients.

    Ali EZ, Khalid MK, Yunus ZM, et al.

    European journal of pediatrics 2016; (175(3)):339-46 doi:10.1007/s00431-015-2644-z.

    PMID: 26440671

This page is for informational purposes only and does not constitute medical advice. Your child's metabolic team must guide protein, formula, medication, and sick-day changes.

Get notified when new evidence is published on Carbamoyl-phosphate synthetase 1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.